Related Experiment Video

Updated: Jun 25, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma

Jonathan D Tward1, Charles V Cachoeira, Mohammed E Salama

  • 1University of Utah and Huntsman Cancer Institute, Salt Lake City, UT, USA. jonathan.tward@hci.utah.edu

Cancer Journal (Sudbury, Mass.)
|February 7, 2009
PubMed
Abstract

Insights

Radiotherapy (RT) significantly improves relapse-free survival (RFS) for patients with non-mycosis fungoides (non-MF) primary cutaneous lymphoma (PCL). RT as initial therapy and absence of bulky disease are key factors for better outcomes in PCL management.

Area of Science:

  • Dermatology
  • Oncology
  • Clinical Research

Background:

  • Primary cutaneous lymphoma (PCL) encompasses various non-Hodgkin lymphomas.
  • Mycosis fungoides (MF) is the most common type of PCL, but other subtypes exist.
  • Understanding survival outcomes for non-MF PCL is crucial for treatment planning.

Purpose of the Study:

  • To evaluate overall survival and relapse-free survival (RFS) in patients diagnosed with non-mycosis fungoides (non-MF) primary cutaneous lymphoma (PCL).

Main Methods:

  • Retrospective analysis of 38 patients with PCL (excluding MF) treated between 1993 and 2006.
  • Kaplan-Meier method used for survival statistics estimation.
  • Cox regression analysis for univariate and multivariate significance testing.

Main Results:

  • Overall survival at 5 and 10 years was 97% and 78%, respectively.
  • Relapse-free survival (RFS) at 5 and 10 years was 30% and 22%, respectively.
  • Radiotherapy (RT) as initial therapy improved 5- and 10-year RFS to 48% and 36%; absence of bulky disease also significantly improved RFS.

Conclusions:

  • Radiotherapy (RT) as part of initial therapy enhances local control and relapse-free survival (RFS) in patients with non-MF PCL.
  • Absence of bulky disease is another significant factor associated with improved RFS.
  • These findings support the role of RT in managing non-MF PCL.

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...